---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-012748"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:47:16.927824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences raises $6.2M in public offering, regains Nasdaq bid price compliance

## Summary
- Gross proceeds ~$6.2M from sale of 128,470 shares and 1,236,530 pre-funded warrants, plus 2,730,000 Class D warrants at $4.53 combined price.
- Class D warrants exercisable at $4.53/share, expire in 5 years; pre-funded warrants at $0.0001/share, no expiration.
- Net proceeds to fund Phase 1a/1b studies for GEM-SSI (surgical site infection) and GEM-AKI (cardiac surgery AKI), plus preclinical GEM-CKD work.
- Nasdaq confirmed on Feb 8, 2024 that REVB regained compliance with minimum $1.00 bid price rule after 11 consecutive trading days above $1.

## SEC filing metadata
- accession: 0000950170-24-012748
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/revb-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-012748
- JSON: https://secwatch.observer/filing/0000950170-24-012748.json
- Plain text: https://secwatch.observer/filing/0000950170-24-012748.txt

## Key facts
- Material Agreements
  REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Value: gross proceeds of approximately $6.2 million
  - Effective: 2024-02-01
  source text: On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm
- Material Agreements
  REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain purchasers
  - Value: gross proceeds of approximately $6.2 million
  - Effective: 2024-02-01
  source text: On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) 128,470 shares of its common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants to purchase 1,236,530 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying two warrants to purchase 2,730,000 shares of Common Stock (the “Class D Common Stock Warrants”) at a combined offering price of $4.53 per share of Common Stock and associated two Class D Common Stock Warrants, or $4.5299 per Pre-Funded Warrant and associated two Class D Common Stock Warrants, resulting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.